HeartBeam Shares Are Trading Higher After the FDA Granted the Company 510(k) Clearance of Its System for Comprehensive Arrhythmia Assessment.
HeartBeam Shares Are Trading Higher After the FDA Granted the Company 510(k) Clearance of Its System for Comprehensive Arrhythmia Assessment.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.